DelveInsight’s, “Celiac Disease Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Celiac Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Celiac Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Celiac Disease Treatment Landscape @ https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight

Key Takeaways from the Celiac Disease Pipeline Report

• On July 01, 2026- Teva Branded Pharmaceutical Products R&D LLC initiated a trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease. The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease. A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease. The expected trial duration per participant is approximately 86 weeks.
• In May 2026- Chugai Pharmaceuticals conducted a main aim is to see how DONQ52 works to improve small intestinal damage and reduce celiac-related symptoms due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.
• DelveInsight’s Celiac Disease pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Celiac Disease treatment.
• The leading Celiac Disease Companies such as Teva Pharmaceutical Industries Ltd., Sanofi, Forte Biosciences, Inc., Takeda, Anokion, Entero Therapeutics, Amgen, Topas Therapeutics, Mozart Therapeutics Australia Pty Ltd, Barinthus Biotherapeutics, Hoffmann Roche, Immunic Therapeutic, Ahead Therapeutics, Equillium, Parvus Therapeutics and others.
• Promising Celiac Disease Pipeline Therapies such as KAN-101, Amlitelimab, TPM502, Ritlecitinib, ALV003, TEV-53408 and others.

Gain in-depth knowledge of key Celiac Disease Clinical Trials, emerging drugs, and market opportunities @ Celiac Disease Ongoing Clinical Trials Assessment

The Celiac Disease Pipeline Report provides a disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Celiac Disease Pipeline Report also highlights the unmet needs with respect to Celiac Disease.

Celiac Disease Overview

Celiac disease is an autoimmune disorder in which the small intestine mounts an immune-mediated response to dietary gluten, a protein found in wheat, barley, and rye. While historically regarded as a gastrointestinal condition primarily causing malabsorption, it is now recognized as a systemic autoimmune disorder. The disease manifests in genetically susceptible individuals and persists lifelong, leading to immune-driven damage to the intestinal lining upon gluten exposure. This damage is characterized by villous atrophy, crypt hyperplasia, and infiltration of immune cells into the lamina propria, resulting in malabsorption of essential nutrients, including micronutrients, fat-soluble vitamins, iron, vitamin B12, and folate.

Celiac Disease Emerging Drugs Profile

• TEV-53408: Teva Pharmaceutical Industries Ltd.

TEV-53408 is an experimental monoclonal antibody with subcutaneous route of administration targeting interleukin-15 (IL-15) to reduce the immune-mediated intestinal inflammation triggered by gluten in individuals with celiac disease. The FDA’s Fast Track designation for TEV-53408 highlights both the therapy’s potential and the significant unmet medical need for patients with this condition. Currently, the drug is in Phase II stage of its clinical study for the treatment of Celiac Disease.

• MTX-101: Mozart Therapeutics

MTX-101 is a bispecific autoimmune checkpoint inhibitor designed to restore immune balance. Its dual-target configuration binds CD8 Treg receptors KIR and CD8 to selectively activate CD8 regulatory T cells while enhancing the therapy’s specificity. MTX-101 functions by reinstating CD8 Treg activity and promoting the cytolytic elimination of pathogenic CD4 T cells. It is being developed for the treatment of early-stage and slowly progressing autoimmune diseases, including type 1 diabetes mellitus and celiac disease. Currently, the drug is in Phase I/II stage of its clinical study for the treatment of Celiac Disease.

• VTP-1000: Barinthus Biotherapeutics

VTP-1000 is an investigational immunotherapy from Barinthus Biotherapeutics designed to restore immune tolerance in celiac disease. Using the SNAP-Tolerance Immunotherapy (SNAP-TI) platform, it co-delivers gluten-derived peptide antigens with the immunomodulator rapamycin via self-assembled nanoparticles administered intramuscularly. These nanoparticles target antigen-presenting cells, promoting a shift from pathogenic T effector cells to regulatory T cells, thereby reducing inflammation and tissue damage from gluten exposure. Currently, the drug is in Phase I stage of its clinical study for the treatment of Celiac Disease.

The Celiac Disease Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Celiac Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Celiac Disease Treatment.
• Celiac Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Celiac Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Celiac Disease market

Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Celiac Disease Unmet Needs

Celiac Disease Companies

Teva Pharmaceutical Industries Ltd., Sanofi, Forte Biosciences, Inc., Takeda, Anokion, Entero Therapeutics, Amgen, Topas Therapeutics, Mozart Therapeutics Australia Pty Ltd, Barinthus Biotherapeutics, Hoffmann Roche, Immunic Therapeutic, Ahead Therapeutics, Equillium, Parvus Therapeutics and others.

Celiac Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Celiac Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

See the latest progress in Celiac Disease Drug Development and Clinical Research @ Celiac Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Celiac Disease Pipeline Report

• Coverage- Global
• Celiac Disease Companies- Teva Pharmaceutical Industries Ltd., Sanofi, Forte Biosciences, Inc., Takeda, Anokion, Entero Therapeutics, Amgen, Topas Therapeutics, Mozart Therapeutics Australia Pty Ltd, Barinthus Biotherapeutics, Hoffmann Roche, Immunic Therapeutic, Ahead Therapeutics, Equillium, Parvus Therapeutics and others.
• Celiac Disease Pipeline Therapies- KAN-101, Amlitelimab, TPM502, Ritlecitinib, ALV003, TEV-53408 and others.
• Celiac Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Celiac Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Celiac Disease Pipeline Analysis Today! @ Celiac Disease Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Celiac Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Celiac Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Mid Stage Products (Phase II)
10. TEV-53408: Teva Pharmaceuticals Industries Ltd.
11. Early Stage Products (Phase I)
12. VTP-1000: Barinthus Biotherapeutics
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Celiac Disease Key Companies
17. Celiac Disease Key Products
18. Celiac Disease- Unmet Needs
19. Celiac Disease- Market Drivers and Barriers
20. Celiac Disease- Future Perspectives and Conclusion
21. Celiac Disease Analyst Views
22. Celiac Disease Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/celiac-disease-pipeline-insight